Germany acted as reference member state and the 28 concerned member states decided to recognize the approval granted in 2006 by the German medicines agency (BfArM) of this new product in its two dosage forms containing lercanidipine 10mg/enalapril 10mg and lercanidipine 10mg/enalapril 20mg. The product is already on the market in Germany as from 2007.
Giovanni Recordati, chairman and CEO of Recordati, said: “We will initiate launches in all these countries, in which lercanidipine has already obtained the physicians’s appreciation, gradually as from the second half of the year. The new product will be sold directly by our marketing organizations in most of the European pharmaceutical market.”